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↑ What is "already known" in this topic: {#box1}
========================================

There is evidence that ATP2B1 and STK39 polymorphism are associated with the risk of essential hypertension. The majority of evidences are from European and East Asian populations and the results are not all consistent. There was no data available considering the relation of these genes with essential hypertension in Iranian population.

→ What this article adds: {#box2}
=========================

Our data indicated that variants in ATP2B1 and STK39 genes probably do not have a significant effect on the risk of essential hypertension in Iranian population.

Introduction {#s1}
============

Blood pressure (BP) is a quantitative and highly variable trait in humans ([@R1])\[1\]. There is a strong positive association between BP and cardiovascular disorders (CVD) such as stroke, heart failure and myocardial infraction ([@R2]). High BP or hypertension is a predominant risk factor for CVD which is preventable. It is estimated that about 31% of world's adults had hypertension in 2010, although this is a mean and hypertension prevalence can be very variable among different countries and races ([@R3]). The age-standardized prevalence of hypertension have been reported to be about 41.8% in a large cohort of Iranian population ([@R4]). Essential or primary hypertension is defined as high BP with the absent of secondary causes such as renal failure, pheochromocytoma, aldosteronism, or other causes which accounts for 95% of all cases ([@R5]). Both environmental and genetic factors are involved in the development of essential hypertension. The heritability of BP is estimated to be between 30-60% which shows a significant contribution of genetics to this trait ([@R6]), and because of that many researches have been dedicated to find genetic components of hypertension.

ATPase plasma membrane Ca2+ transporting 1 (ATP2B1) plays a critical role in intracellular calcium homeostasis ([@R7]). This gene was shown to be related to systolic blood pressure (SBP), diastolic blood pressure (DBP), and hypertension in a genome wide association study ([@R8]). It has also been shown that variations of ATP2B1 are associated with hypertension in East Asians ([@R9]) and European populations ([@R10]). STK39 (serine/threonine kinase 39) is a sterile 20-like-related proline-alanine-rich kinase that keep the salt-water homeostasis by mediating the phosphorylation of numerous cation-chloride-coupled cotransporters ([@R11]). The possible link between STK39 and hypertension was first reported in a genome wide association (GWA) study in 2009 ([@R12]). After that, replication studies were performed in different ethnic groups, but the results are not consistent ([@R13]).

To the best of our knowledge, there is no study reporting the association of ATP2B1 or STK39 variations with susceptibility to hypertension in Iranian population. Here we selected a SNP in each of these genes (ATP2B1 rs2681472 and STK39 rs35929607) which were previously studied in other populations. We investigated in our study the association of rs2681472 and rs35929607 with essential hypertension through a case-control study in an Iranian population.

Methods {#s2}
=======

Study population {#s2-0-1}
----------------

Our research was a case-control study comprising 200 patients with essential hypertension as case group and 200 healthy individuals as control group. Both case and control groups were randomly selected from individuals referred to clinics of Fasa University Hospital. Diagnosis of essential hypertension was made upon JNC-8 criteria of BP greater than 140/90 on two separate measurements, at least 15 minutes apart, in the absence of secondary causes. Individuals in control group were free of hypertension without any previous history and their BP was measured before taking the blood sample as well. In addition to SBP and DBP, a set of demographic (Age, BMI, Sex, Smoking and Diabetes Mellitus (DM) status) and general laboratory tests (HB, Cr, FBS, TG, LDL and HDL) were measured in all samples, which is reported in [Table 1](#T1){ref-type="table"}. Individuals with history of other CVD including coronary artery disease, systolic heart failure, cardiomyopathies and significant valvular diseases were excluded from the study. Individuals in case and control groups were all ethnically Iranian. Informed consent was taken from all participants and the study was approved by the ethic committee of Fasa University of Medical Sciences (IR.FUMS.REC.1394.8).

###### Demographic and laboratory data of case and control groups

  ----------------- ---------------- ----------------- ----------
  Variable          Case (N=200)     Control (N=200)   p-value
  Age (year)        57.22 ± 9.34     56.59 ± 12.98     0.57
  BMI (Kg/m ^2^ )   24.67 ± 4.17     24.51 ± 3.66      0.68
  Sex (F/M)         112/88           119/81            0.41
  Smoking (%)       22 (11)          14 (7)            0.16
  DM (%)            15 (7)           8 (4)             0.13
  SBP (mmHg)        140.59 ± 23.42   113.22 ± 9.96     \<0.0001
  DBP (mmHg)        84.86 ± 11.89    72.12 ± 8.55      \<0.0001
  HB (g/dL)         12.81 ± 1.78     12.49 ± 2.07      0.10
  Cr (mg/dL)        1.14 ± 1.38      1.15 ± 0.32       0.69
  FBS (mg/dL)       125.15 ± 62.68   120.52 ± 58.41    0.44
  TG (mg/dL)        128.50 ± 80.60   118.66 ± 25.84    0.10
  LDL (mg/dL0       106.57 ± 45.12   100.53 ± 47.23    0.19
  HDL (mg/dL)       43.95 ± 8.43     45.12 ± 5.87      0.10
  ----------------- ---------------- ----------------- ----------

BMI: body mass index, DM: diabetes mellitus, SBP: systolic blood pressure, DBP: diastolic blood pressure, HB: hemoglobin, Cr: creatinine, FBS: fasting blood sugar, TG: triglyceride, LDL: low density lipoprotein, HDL: high density lipoprotein

DNA extraction and genotyping {#s2-0-2}
-----------------------------

About 3ml of peripheral blood was taken from every participant and DNA was extracted using a standard salting out method. PCR-RFLP method was used for genotyping of rs2681472 and rs35929607. The PCRs were performed using 20 μl of reaction mixture containing 0.4 µM of each primer, 200 mM of dNTPs, 2 mM MgCl~2~ and 1 unit of Taq DNA polymerase (Amplicon, Denmark). The products were digested using appropriate restriction enzymes in 37 °C for 3 hours. The details of PCR programs and digestions are described in [Table 2](#T2){ref-type="table"}. The digested PCR products were separated using 3% agarose gel electrophoresis staining with Power load (Kawsar Biotech, Iran).

###### The Primer sequences and digestion conditions for studied polymorphisms

  --------------- ---------------------------------- ----------------------- --------------------- --------- -------------------------- ---- ---------
  Polymorphisms   Primer sequences (5à3)             PCR conditions (°C/s)   Restriction enzyme\   Alleles   DNA fragment\                   
                                                                             digestion                       size (bp)                       

  Denature        Annealing                          Extension                                                                               

  rs2681472       F: TCTGAGGATGTGGCATTTGA\           95/35                   58/30                 72/30     PvuII at 37C for 3 hours   T\   203\
                  R: CCCAGTAAGGCCAGAGATCA                                                                                               C    141+62

  rs35929607      F: AACACTCTCACAAGAAGAGATCCCAGTG\   95/35                   61/40                 72/45     MspI at 37°C for 3 hours   A\   349\
                  R: CTCCCAGGTCGTTTTCAAACAAAAATAA                                                                                       G    201+148
  --------------- ---------------------------------- ----------------------- --------------------- --------- -------------------------- ---- ---------

Statistical Analysis {#s2-0-3}
--------------------

Quantitative variables are presented as mean ± standard deviation, and difference between groups was determined using student's t-test. The Hardy-Weinberg equilibrium was estimated in the population (whole study population and also control group) using chi-squared test. Chi-square test was also used to compare the genotype and allele frequencies between the case and the control groups. Additionally, the association of genotypes with essential hypertension was assessed under log-additive, dominant and recessive genetic models using SNPassoc package of R program ([@R14]). All statistical analysis was carried out using R version 3.2.3.

Results {#s3}
=======

Four hundred subjects, 200 with hypertension (mean age ± standard deviation: 57.22±9.34 years) and 200 healthy sex and age matched controls (mean age ± standard deviation: 56.59±12.98 years) were included in this study. Except for SBP and DPB (which was expected) group analysis revealed no significant difference in demographic and laboratory data of the case and the control groups ([Table 1](#T1){ref-type="table"}).

The studied population was in Hardy-Weinberg equilibrium for both SNPs (p\>0.05). The distribution of genotype and allele frequencies were not different between the case and the control groups for any of rs2681472 and rs35929607 polymorphisms ([Table 3](#T3){ref-type="table"}). There was also no association between essential hypertension and studied polymorphisms when analyzing under different genetic models ([Table 4](#T4){ref-type="table"}).

###### Genotype and allele frequencies in case and control groups

  -------------------- -------------- -------------------------- ----------- ------------------------ ------------ ------------ ----------- ------ ------ -----------
  Gene (SNP)           Subjects (n)   Genotype frequencies (%)   p           Allele frequencies (%)   p            OR           95% CI                    
                                      TT                         TC          CC                                    T            C                         
  ATP2B1 (rs2681472)   Case (200)     86 (43)                    91 (45.5)   23 (11.5)                0.99         263 (66)     137 (34)    1      1.01   0.75-1.35
  Control (200)        86 (43)        92 (46)                    22 (11)     264 (66)                 136 (34)                                            
  Total (400)          172 (43)       183 (45.7)                 45 (11.3)   527 (65.8)               273 (34.2)                                          
                       AA             AG                         GG          A                        G                                                   
  STK39 (rs35929607)   Case (200)     118 (59)                   70 (35)     12 (6)                   0.56         306 (76.5)   94 (23.5)   0.80   0.95   0.69-1.32
  Control (200)        112 (56)       79 (39.5)                  9 (4.5)     303 (76)                 97 (24)                                             
  Total (400)          230 (58)       149 (37)                   21 (5)      609 (76)                 191 (24)                                            
  -------------------- -------------- -------------------------- ----------- ------------------------ ------------ ------------ ----------- ------ ------ -----------

###### Analysis of Genotype distribution between the case and the control groups

  -------------------- -------- ---------------------------------- ----------------------------- -----------------------------
  Gene (SNP)                    log-Additive\                      Recessive\                    Dominant\
                                (TT=0, TC=1 , CC=2)                (TT and TC vs CC)             (TC and CC vs. TT)

  \                    p        0.98                               0.87                          1
  ATP2B1 (rs2681472)                                                                             

                       OR       1.05                               1.05                          1

                       95% CI   0.54-2.02                          0.57-1.96                     0.67-1.49

                                log-Additive (AA=0, AG=1 , GG=2)   Recessive (AA and AG vs GG)   Dominant (GG and AG vs. AA)

  STK39 (rs35929607)   p        0.80                               0.50                          0.54

                       OR       0.96                               1.35                          0.88

                       95% CI   0.69-1.33                          0.59-1.32                     059-1.32
  -------------------- -------- ---------------------------------- ----------------------------- -----------------------------

Discussion {#s4}
==========

In the current study, we demonstrated that there is no association between essential hypertension and ATP2B1 rs2681472 and STK39 rs35929607 in a cohort of Iranian population. The genotypes were evenly distributed among patients with hypertension and control group and still allele frequencies were not different.

ATP2B1 have been reported as a candidate gene for blood pressure in several GWA studies in people of European, and east Asian origin (Japanese, Chinese and Koreans) ([@R8], [@R15]-[@R17]). The gene is involved in calcium homeostasis which is critical for normal vascular contraction ([@R18]), the function that could be related to BP regulation. ATP2B1 variants have been widely studied in east Asian populations through replication studies, and the results are in favor of ATP2B1 involvement in hypertension in these populations ([@R19]). Despite this, there are only a few studies reporting the association of ATP2B1 variations and risk of hypertension in other populations. Nonetheless, ATP2B1 was not associated with blood pressure in an African American cohort ([@R20]), which is consistent with our study findings. Based on our findings we assume that ATP2B1 is not a significant determinant in the pathophysiology of hypertension in Iranian population or there may be a protective gene functioning in this population.

Since the introduction of STK39 as a candidate gene for essential hypertension in a GWAS, there has been interest toward ([@R8]) delineation of its function in the pathophysiology of hypertension. Results of the replication studies were also mixed and some support the association of STK39 variations with hypertension, like those being conducted in Belgian (rs3754777) ([@R21]), Chinese (rs6433027 and rs3754777) ([@R11]) and Swedish populations (rs35929607) ([@R22]) while others failed to prove any association, such as studies in Chinese (rs6749447, rs3754777, rs35929607, rs4667569, rs4977950) ([@R23]), Korean (rs3754777 and rs6749447) ([@R24]) and British Caucasian populations(rs6749447, rs3754777, rs35929607) ([@R25]). Our study is in agreement with the latter studies and supports a lack of association in Iranian population. Along with the studies with conflicting results in Chinese population ([@R11], [@R23]), two meta-analyses about STK39 and risk of hypertension are also demonstrative of inconclusive findings ([@R13], [@R26]).

It seems that despite many studies that have investigated the association of ATP2B1 and STK39 gene variations with essential hypertension, the results are still inconsistent. It could be concluded that these variations only have significant effect in specific populations and ethnic groups which can be explained by the different genetic backgrounds in various ethnicities. Furthermore, environmental exposures and life styles as hypertension risk factors have different implications and significance among various populations. Similarly, the observed discrepancy regarding this polymorphisms and hypertension in different populations can be attributed to gene-environment interactions which itself can be secondary to the modifier effects like what has been proposed as the mechanism for the attenuation or blunting of the genetic factors. For instance, it has been demonstrated that smoking is a significant risk factor for the association of rs3754777 of STK39 with hypertension ([@R13]). Therefore, investigations in subgroups and taking multiple exposures into account as well would yield in a better understanding to the role of these polymorphisms in the susceptibility to hypertension.

Being a multifactorial disease with a handful of environmental, genetic and behavioral contributors, hypertension must be viewed as a complex outcome. Excluding secondary hypertension, the etiology of essential hypertension cannot be explained by a single determinant like a mutation. There are plenty of modifier and protective traits as well, which mostly are related to life style and genetic factors ([@R27], [@R28]). Polymorphisms that are proposed as candidates for hypertension development in GWASs, then must be studied separately in different populations with special considerations about the confounding effects of diet, life style and behavioral factors. A longitudinal cohort study of non-hypertensive population is the best fit for such association studies and can clearly account for major confounders. This study must be interpreted with its limitations including restricted number of cases, possible confounding factors and limited number of studied SNPs. A larger cohort of seemingly healthy individuals with long enough follow ups to get the hypertension as an outcome, will properly address the causality of these polymorphisms in hypertension.

Conclusion {#s5}
==========

Our study indicates that rs2681472 and rs35929607 and probably ATP2B1 and STK39 genes do not have a significant effect on susceptibility to hypertension in Iranian population. Functional in vitro studies may help to clarify the exact effect of these variations in essential hypertension. More studies are still required to validate our study results.
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